![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ImmunoGen Files IND for Its HuC242-DM4 Targeted Anticancer Compound
ImmunoGen Files IND for Its HuC242-DM4 Targeted Anticancer Compound
April 1, 2005
ImmunoGen has submitted an investigational new drug application to the FDA for its huC242-DM4 targeted anticancer therapeutic.
HuC242-DM4 -- a Tumor-Activated Prodrug compound -- is in development by the company for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small cell lung cancers. The compound is wholly owned by ImmunoGen.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct